- Ogivri is the first biosimilar to Herceptin (trastuzumab) to be approved and launched in Australia for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer and will be available on the Pharmaceutical Benefits Scheme
- The TGA’s approval of Ogivri is based on data which demonstrated bio-similarity to Herceptin with no clinically meaningful differences in efficacy, safety, purity and potency. The HERITAGE study resulted in bio-similarity in terms of reduction in tumor size @24 wks. & OS @48 wks.
- Ogivri is a biosimilar of Roche’s Herceptin and has received FDA’s approval in Dec’2017 for HER2-overexpressing breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma
Click here to read full press release/ article | Ref: Biocon | Image: Patch